| 0.0532 0 (0%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.78 |
1-year : | 1.16 |
| Resists | First : | 0.67 |
Second : | 1 |
| Pivot price | 0.24 |
|||
| Supports | First : | 0.15 |
Second : | 0.12 |
| MAs | MA(5) : | 0.18 |
MA(20) : | 0.23 |
| MA(100) : | 0.24 |
MA(250) : | 0.45 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 1.6 |
D(3) : | 2.9 |
| RSI | RSI(14): 40 |
|||
| 52-week | High : | 1.29 | Low : | 0.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LIXTW ] has closed above bottom band by 9.3%. Bollinger Bands are 39.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.49 - 0.49 | 0.49 - 0.5 |
| Low: | 0.15 - 0.15 | 0.15 - 0.15 |
| Close: | 0.15 - 0.15 | 0.15 - 0.15 |
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Wed, 27 Mar 2024
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD - GlobeNewswire
Thu, 21 Mar 2024
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy ... - Yahoo Finance
Tue, 27 Feb 2024
Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and ... - GlobeNewswire
Mon, 26 Feb 2024
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI - Yahoo Finance
Mon, 13 Nov 2023
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations - Yahoo Finance
Mon, 09 Oct 2023
LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|